Frankfurt
20.08.26 | 08:05
1,264 Euro
-2,47 % -0,032
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.07. | Orexo weitet Verlust im zweiten Quartal aus - Umsatz verfehlt die Schätzungen | 1 | Investing.com Deutsch | ||
| 16.07. | Orexo AB: Orexo Q2 2026 Interim Report | 138 | GlobeNewswire (Europe) | Building momentum for the next chapterFinancial summary April - JuneTotal net revenues of SEK 3.5 m (4.8)Net earnings for the period is SEK -102.5 m (-97.5)Cash flow for the period is SEK -109.3 m (2.2)Earnings... ► Artikel lesen | |
| 09.06. | Orexo AB: Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships | 197 | GlobeNewswire (Europe) | Uppsala, Sweden - June 9, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announced that the company is strengthening its business development efforts through the appointment of Raheleh Nassaji... ► Artikel lesen | |
| 19.05. | Orexo announces positive outcome from an in-vivo study of OX390 | 850 | PR Newswire | UPPSALA, Sweden, May 19, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole... ► Artikel lesen | |
| 19.05. | Orexo AB: Orexo announces positive outcome from an in-vivo study of OX390 | 203 | GlobeNewswire (Europe) | Uppsala, Sweden - May 19, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces positive data from a pre-clinical in-vivo study on the nasal absorption of atipamezole when delivered with... ► Artikel lesen | |
| 07.05. | Orexo AB: Report from Orexo AB's annual general meeting May 7 2026 | 359 | GlobeNewswire (Europe) | Election of the board of directors and auditorThe annual general meeting in Orexo AB (publ) on 7 May 2026 resolved, in accordance with the nomination committee's proposal, that the number of board members... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 28.04. | Orexo AB: Orexo Q1 2026 Interim Report | 175 | GlobeNewswire (Europe) | Well positioned to advance pipeline to value inflection pointsFinancial summary January - MarchTotal net revenues of SEK 5.0 m (13.2)Net earnings for the period is SEK -105.2 m (-90.6)Cash flow for... ► Artikel lesen | |
| 06.03. | Invitation & Agenda: Orexo R&D Day on March 24 | 399 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY) today invites investors, analysts and media to attend the company's R&D Day on March 24, 2026. The... ► Artikel lesen | |
| 06.03. | Orexo changes the organizational structure and management team to increase focus on development of new products | 542 | PR Newswire | UPPSALA, Sweden, March 6, 2026 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management... ► Artikel lesen | |
| 06.03. | Orexo AB: Orexo changes the organizational structure and management team to increase focus on development of new products | 227 | GlobeNewswire (Europe) | Uppsala, Sweden - March 6, 2026 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces changes to its organizational structure and management team. The changes are a result of the divestment of... ► Artikel lesen | |
| 19.02. | Orexo AB: Orexo: Conversion of Class C shares into ordinary shares and conveyance of ordinary shares within the framework of long-term performance-based incentive programs | 446 | GlobeNewswire (Europe) | The Board of Orexo AB (publ) has today decided to convert 416,417 Class C shares into ordinary shares and to subsequently convey 416,417 ordinary shares to certain participants in the long-term incentive... ► Artikel lesen | |
| 05.02. | Orexo AB: Orexo Interim Report Q4 2025, incl. Full Year Report | 793 | GlobeNewswire (Europe) | Turning a transformative deal into new opportunitiesQ4 2025 highlights›Dexcel Pharma USA aquired all rights to Zubsolv® US on December 31, at a purchase price of USD 91 m plus the value of inventory... ► Artikel lesen | |
| 22.12.25 | Orexo AB: Orexo Enters Into Agreement with Dexcel Pharma USA to Divest US Rights to Zubsolv | 718 | GlobeNewswire (Europe) | · An asset purchase agreement has been signed with Dexcel Pharma USA, which will acquire the full rights to Zubsolv® in the US, at a purchase price of USD 91 million plus the value of inventory at closing... ► Artikel lesen | |
| 23.10.25 | Orexo AB: Orexo Q3 2025 Interim Report | 281 | GlobeNewswire (Europe) | Unlocking the potential of the AmorphOX® technologyQ3 2025 highlights› Total net revenues of SEK 118.7 m (136.5)› EBITDA of SEK -9.8 m (-0.7), including a negative impact from costs associated with... ► Artikel lesen | |
| 01.10.25 | Orexo AB: Orexo strengthens innovation and research with move to new premises | 313 | GlobeNewswire (Europe) | Uppsala, Sweden, October 1, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY) is taking the next step in its development journey by relocating to new, modern premises in Uppsala Science Park. The move... ► Artikel lesen | |
| 29.09.25 | Orexo AB: Orexo US Awarded USD 8 Million by BARDA for OX390 Development Partnership | 521 | GlobeNewswire (Europe) | Uppsala, Sweden - September 29, 2025 - Orexo AB (Publ.), (STO:ORX) (OTCQX:ORXOY), today announced its wholly owned US subsidiary, Orexo US, Inc., has been awarded USD 8 million in funding by the Biomedical... ► Artikel lesen | |
| 05.09.25 | Orexo's AmorphOX technology may pave the way for intranasal GLP-1 medication | 1.205 | PR Newswire | A preclinical pharmacokinetic in-vivo study has been conducted in which the AmorphOX® technology was used to develop three powder-based intranasal formulations with semaglutide, which were... ► Artikel lesen | |
| 29.08.25 | Seminar: IP That Matters - Behind Orexo's Milestone Patent Win at the US Court | 522 | PR Newswire | UPPSALA, Sweden, Aug. 29, 2025 /PRNewswire/ -- Orexo (publ.), (STO: ORX) (OTCQX: ORXOY) in collaboration with its advisory international law firms Potter Clarkson LLP and Steptoe LLP, will... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,238 | -0,49 % | Curaleaf Holdings, Inc.: Curaleaf Launches Take-Over Bid to Acquire Aurora Cannabis, Invites Aurora Shareholders to Tender to the Bid | Formal offer and take-over bid circular filed and will be delivered to Aurora shareholders
Offer provides total implied consideration of US$4.00 per share, representing... ► Artikel lesen | |
| ABBVIE | 224,00 | -0,13 % | Warum Eli Lilly 3,8 Milliarden US-Dollar auf Psychedelika setzt - und Emyria plötzlich an einem entscheidenden Engpass sitzt | ||
| TILRAY BRANDS | 4,010 | +0,12 % | Tilray Brands, Inc.: Tilray Medical begrüßt die positiven Entwicklungen im deutschen Rechtsrahmen für medizinisches Cannabis und setzt sich für dessen kontinuierliche Weiterentwicklung ein | Als weltweit führender Anbieter von medizinischem Cannabis unterstützt Tilray Medical eine Weiterentwicklung der Regulierung, die das Vertrauen der Ärzteschaft stärkt, den Zugang der Patienten schützt... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 56,30 | +0,41 % | Schlafender Biotech-Riese vor der nächsten Wachstumsphase? BioNTech, Emyria und die neue Macht der Datenplattformen | ||
| TEVA | 31,800 | +0,95 % | Teva: FDA nimmt Zulassungsantrag für Tourette-Medikament Ecopipam an | Die US-Arzneimittelbehörde FDA hat den Zulassungsantrag von Teva Pharmaceuticals für den Wirkstoff Ecopipam zur Prüfung angenommen. Die US-Tochter von Teva Pharmaceutical Industries teilte mit, dass... ► Artikel lesen | |
| BAUSCH HEALTH | 5,750 | -1,54 % | Bausch Health Companies Inc.: Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board | LAVAL, QC, Aug. 6, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas... ► Artikel lesen | |
| BIONANO GENOMICS | 1,215 | +0,41 % | Bionano Genomics: Bionano Announces Hiring of Chief Scientific Officer | SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a leader in genome analysis solutions, today announced the appointment of Alex Hastie, Ph.D., as its Chief Scientific... ► Artikel lesen | |
| OPKO HEALTH | 1,220 | +6,09 % | OPKO Health Secures $125 Million Financing Against Mazdutide Royalties | ||
| JAGUAR HEALTH | 0,885 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Reports Second Quarter 2026 Financials | Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking... ► Artikel lesen | |
| KEENOVA THERAPEUTICS | - | - | Keenova Therapeutics: Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX (collagenase clostridium histolyticum) for Hammer Toe | First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical... ► Artikel lesen | |
| AVALO THERAPEUTICS | 18,000 | +6,01 % | Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates | Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1ß... ► Artikel lesen | |
| BAYER | 48,610 | -0,82 % | Bayer: Das sind aktuell die wichtigen Schlüsselzonen | Nach dem Comeback Ende Juni hat die Bayer-Aktie eine Verschnaufpause eingelegt und dabei neue technische Zonen ausgebildet. Im Mittelpunkt stehen dabei die Unterstützung an der 50-Tage-Linie sowie das... ► Artikel lesen | |
| MERCK KGAA | 138,05 | -0,22 % | Bundeskartellamt gibt Übernahme von Bio-Techne durch Merck KGaA (Darmstadt) frei | Das Bundeskartellamt hat heute die geplante Übernahme des US-amerikanischen Biotechnologieunternehmens Bio-Techne, Minneapolis, durch die Merck KGaA aus Darmstadt freigegeben. Das Vorhaben ist auch... ► Artikel lesen | |
| NOVO NORDISK | 39,550 | -0,11 % | Novo Nordisk gegen Eli Lilly: Darum spitzt sich der Streit jetzt zu | Die Aktie von Novo Nordisk war bis Mitte 2024 einer der großen Überflieger der Branche und in Europa. Seitdem ging es bei dem Wert aber steil bergab. Insbesondere die starke Konkurrenz aus den USA macht... ► Artikel lesen | |
| PFIZER | 23,850 | +0,17 % | Pfizer-Partner Valneva: Aktie hebt ab - Zeckenimpfstoff vor dem Durchbruch? | Nachdem es lange ruhig war bei Valneva, meldet sich die Aktie des Biotechunternehmens am heutigen Freitag eindrucksvoll zurück. Auf der Handelsplattform Tradegate geht es mehr als 17 Prozent nach oben.... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.